UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
On December 15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting a cautious view on the stock amid competitive pressures and mixed industry dynamics. UBS's rating and target were reiterated in recent analyst research, with the Neutral outlook suggesting neither strong upside nor a compelling near-term buy signal. A key recent development supporting Novo Nordisk A/S (NYSE:NVO)'s growth strategy occurred on December 12, 2025, when the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending EU approval of a higher 7.2 mg dose of Wegovy (semaglutide). This higher dose demonstrated significantly greater average weight loss in clinical trials compared to the currently approved 2.4 mg dose and, if formally approved by the European Commission, could become available in early 2026. The higher Wegovy dosage is also under regulatory review in the U.S., U.K., and
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs [Yahoo! Finance]Yahoo! Finance
- This is how exposed European Big Pharma is to the U.S. [MSNBC.com]MSNBC.com
- Prediction: 1 Healthcare Giant Set to Soar in 2026 [Yahoo! Finance]Yahoo! Finance
- Obesity pill race heats up [CNBC]CNBC
- Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website